Full-Service CROs
CROs managing complete clinical trial programs across all phases.
Market snapshot
These figures describe Clinical Research Organizations (CRO) (4.9.2), the segment that Full-Service CROs sits within — not Full-Service CROs on its own.
Within biotech R&D (NAICS 541714, a broad ~$91B research category) and life-sciences services; CROs are not cleanly separated, so the segment is not separately sized here.
Business model & economics
Revenue model
Fee-for-service and full-service trial-management contracts
Key economics
- Recurring revenue
- High
- EBITDA margin
- 15–25%
- Capex intensity
- Low
multi-year program relationships
Characteristics
- Large, consolidated drug-development outsourcing market.
- Trial complexity and R&D outsourcing drive demand.
- Sensitive to the biotech funding cycle.
Geographic concentration
Clinical research organizations concentrate around the life-sciences clusters — Massachusetts and the Maryland biotech corridor — with Delaware and California close behind.
U.S. Census Bureau — 2022 County Business Patterns (establishments by state), NAICS 541714. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- CRO majors
- Life-sciences-services consolidators
- PE-backed platforms
What’s driving deals
- Consolidation around full-service CRO platforms.
- Biopharma R&D-outsourcing growth.
- Trial-complexity and capability demand.
Find Full-Service CROs acquisition targets
Search Acquisera’s index for companies classified under Full-Service CROs (4.9.2.1) and build a targeted deal pipeline.
Search companies